Owner Catalent Pharma Solutions, LLC

Inventors Bremel, Robert D.; Miller, Linda U.; Bleck, Gregory T

Agent Spruson & Ferguson

Pub. Number AU-B-2007214314

Parent 2001271614

Filing date 30 August 2007

Wipo publication date 20 September 2007

Acceptance publication date 8 March 2012

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

C07K 14/02 (2006.01) Peptides having more than 20 amino acids

C07K 16/12 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from bacteria

C07K 16/30 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 7/04 (2006.01) Viruses, e.g. bacteriophages - Inactivation or attenuation

C12N 15/82 (2006.01) Mutation or genetic engineering - for plant cells

C12N 15/85 (2006.01) Mutation or genetic engineering - for animal cells

C12N 15/86 (2006.01) Mutation or genetic engineering - Viral vectors

C12N 15/867 (2006.01) Mutation or genetic engineering - Retroviral vectors

C12P 21/02 (2006.01) Preparation of peptides or proteins - having a known sequence of two or more amino acids, e.g. glutathione

C12Q 1/02 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving viable micro-organisms